Shakeel Modak

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Antibody-based targeted radiation to pediatric tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:157S-63S. 2005
  2. ncbi request reprint Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 20:534-46. 2005
  3. ncbi request reprint Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1271-3. 2008
  4. ncbi request reprint Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1934-43. 2004
  5. ncbi request reprint Disialoganglioside directed immunotherapy of neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 25:67-77. 2007
  6. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
  7. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
  8. doi request reprint Neuroblastoma: Therapeutic strategies for a clinical enigma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Cancer Treat Rev 36:307-17. 2010
  9. doi request reprint Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Pediatr Blood Cancer 58:469-71. 2012
  10. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007

Detail Information

Publications48

  1. ncbi request reprint Antibody-based targeted radiation to pediatric tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:157S-63S. 2005
    ..Without substantial policy changes in drug development for orphan indications, however, these agents are not likely to be widely available in the near future...
  2. ncbi request reprint Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 20:534-46. 2005
    ..5 MBq (131)I-8H9 were significantly suppressed compared to controls. Radiolabeled 8H9 effectively targeted RMS xenografts and may have a potential clinical role in radioimmunotherapy...
  3. ncbi request reprint Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1271-3. 2008
    ..5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia...
  4. ncbi request reprint Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1934-43. 2004
    ..To evaluate the efficacy and toxicity of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in patients with relapsed or progressive CNS germ cell tumors (GCTs)...
  5. ncbi request reprint Disialoganglioside directed immunotherapy of neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 25:67-77. 2007
    ..We review the current status of anti-GD2 clinical trials for neuroblastoma and novel preclinical GD2-targeted strategies for this rare but often lethal childhood cancer...
  6. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  7. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
    ..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
  8. doi request reprint Neuroblastoma: Therapeutic strategies for a clinical enigma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Cancer Treat Rev 36:307-17. 2010
    ..It is likely that a combination of therapeutic modalities will be required to improve survival and cure rates...
  9. doi request reprint Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Pediatr Blood Cancer 58:469-71. 2012
    ..Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB...
  10. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  11. doi request reprint A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
    ..The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy...
  12. ncbi request reprint Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:1217-23. 2002
    ..We tested if (1-->3),(1-->4)-beta-D-glucan (beta-glucan) can synergize with anti-GD2 monoclonal antibody (MoAb) 3F8 (mouse IgG3) in therapy of human neuroblastoma xenografts...
  13. doi request reprint Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  14. ncbi request reprint Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 51:557-64. 2002
    ..Given the favorable efficacy and toxicity profile of oral beta- D-glucan treatment, the role of natural products that contain beta-glucan in cancer treatment as an enhancer of the effect of mAb therapy deserves further study...
  15. pmc Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
    ..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
  16. doi request reprint Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:17-22. 2009
    ..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
  17. doi request reprint Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 75:1181-6. 2009
    ..To present a large experience (73 patients) using a standard radiotherapy (RT) protocol to prevent relapse in cranial sites where measurable metastatic neuroblastoma (NB), an adverse prognostic marker, is common...
  18. ncbi request reprint Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hybrid Hybridomics 22:209-18. 2003
    ..Anti-idiotypic antibody may provide a useful tool for optimizing gene transduction of CIR fusion constructs into primary human lymphocytes and their continual expansion in vitro...
  19. doi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
    ....
  20. doi request reprint High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  21. pmc Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 26:4995-6. 2008
  22. doi request reprint Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
    Victoria J Croog
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 78:849-54. 2010
    ..This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT)...
  23. pmc Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:1041-6. 2009
    ..Relapse-free survival (RFS) is a powerful measure of treatment efficacy. We describe the sensitivity of standard surveillance studies for detecting relapse of neuroblastoma (NB)...
  24. ncbi request reprint Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:4888-92. 2004
    ..We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor)...
  25. ncbi request reprint Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 41:508-15. 2003
    ..We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB)...
  26. doi request reprint Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:665-71. 2013
    ..A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB...
  27. ncbi request reprint Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:84-7. 2004
    ..067 mg/kg was injected on day 1. With C/I, irinotecan, 50 mg/m(2) was infused i.v. (1 h) on days 1-5 (total, 250 mg/m(2)). Mesna and granulocyte colony-stimulating factor were used...
  28. ncbi request reprint Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5271-6. 2006
    ..To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations...
  29. doi request reprint High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Cancer 47:84-9. 2011
    ..We used a novel regimen for neuroblastoma (NB) that had responded inadequately to standard chemotherapy which now includes topotecan in induction or second-line therapy...
  30. doi request reprint Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 51:552-4. 2008
    ..Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR...
  31. ncbi request reprint Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:417-22. 2006
    ....
  32. pmc Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:3264-70. 2012
    ..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored...
  33. pmc Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
    Nidale Tarek
    Department of Pediatrics, Sloan Kettering Institute, New York, NY 10065, USA
    J Clin Invest 122:3260-70. 2012
    ..These results indicate that unlicensed NK cells play a key antitumor role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus explaining the potent "missing KIR ligand" benefit in patients with NB...
  34. pmc Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:1168-74. 2011
    ..We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8...
  35. ncbi request reprint Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 92:33-9. 2007
    ....
  36. ncbi request reprint Long-term complications in survivors of advanced stage neuroblastoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pediatr Blood Cancer 45:324-32. 2005
    ..Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease...
  37. ncbi request reprint Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 46:278-84. 2006
    ..We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy...
  38. ncbi request reprint Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:867-77. 2004
    ..Neuroblastoma is uniquely suited for such investigations because of its abundance of surface ganglioside GD2...
  39. ncbi request reprint Brain-sparing radiotherapy for neuroblastoma skull metastases
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1163-8. 2008
    ..The purpose of this study was to describe the technique, outcome and toxicities in patients with high risk NB metastatic to the skull treated with brain-sparing skull radiotherapy (BSRT)...
  40. doi request reprint Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience
    Neil B Desai
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Radiat Oncol Biol Phys 85:e67-72. 2013
    ..Our objectives were to assess the benefit of intensity modulated radiation therapy (IMRT) on toxicity and to update the largest series on radiation for DSRCT...
  41. ncbi request reprint Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Med Pediatr Oncol 41:80-2. 2003
  42. ncbi request reprint Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Med Pediatr Oncol 39:547-51. 2002
    ..We examined DSRCT samples for the expression of two tumor antigens that could serve as possible targets for antibody-based immunotherapeutic approaches...
  43. ncbi request reprint Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:858-62. 2005
    ..Quality of life was a major issue in choosing this regimen for patients whose disease was resistant to standard anti-NB therapies...
  44. doi request reprint Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 119:2789-95. 2013
    ..In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES...
  45. ncbi request reprint Results of multimodal treatment for desmoplastic small round cell tumors
    Dave R Lal
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Surg 40:251-5. 2005
    ..4 years (range, 0.4-11.2 years). CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT. Aggressive surgical resection of these extensive intraabdominal neoplasms correlates with improved patient outcome...
  46. doi request reprint Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections
    Mark L Kayton
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Pediatr Surg 45:1961-6. 2010
    ..Catheter-related bloodstream infections remain costly with no simple prevention. We report preliminary results of a phase I trial of ethanol-lock administration to prevent mediport catheter-related bloodstream infections in children...
  47. ncbi request reprint Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hybrid Hybridomics 21:433-43. 2002
    ..The reduced size resulted in a shorter half-life in vivo, while achieving comparable tumor to nontumor ratio as the native antibody 8H9. However, its in vitro activity in antibody-dependent cell-mediated cytotoxicity was modest...
  48. ncbi request reprint High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...